Pathway Irinotecan Pathway, Pharmacodynamics

Model non-tissue specific cancer cell displaying genes which may be involved in the irinotecan pathway.
Irinotecan Pathway, Pharmacodynamics
sn-38 Irinotecan sn-38
clickable pathway icons
Reproductions of this diagram can be used with permission from PharmGKB. Request permission


SN38 Mechanism

SN-38, the active metabolite of irinotecan (IRI), is transported into and out of the cell by ABCC2, ABCB1, and ABCG2 [Article:20602618] . This active metabolite is a DNA Topoisomerase I inhibitor which leads to cancer cell death. Topoisomerase I is a nuclear enzyme required in replication, responsible for unwinding DNA and preventing lethal strand breaks [Articles:22647487, 19604089]. SN-38 is cytotoxic and destabilizes the Topoisomerse I-DNA covalent complex formed in colorectal cancerous cells (CRC). SN-38 causes irreversible double strand breaks which lead to S phase arrest followed by cell death. To do so, SN-38 attaches to the complexes and blocks future replication forks preventing repairs of double strand breaks [Articles:23422270, 19604089, 21997136].


Little research has been done on identifying the impact of pharmacodynamics genes on variation in patient response to IRI, but genes likely involved in the process have been targeted: TOP1, PARP1, TDP1, XRCC1, ADPRT, CDC45L, and NF-kB1. Although the genes listed are involved in the dynamics of IRI in human cells, their role in patient response variation is minimal, unlike the impact of pharmacogenomics in the pharmacokinetics of IRI. Future research should be done regarding varied expression of the PXR protein (encoded by NR1I2) on the rate of SN-38 glucoronidation [Articles:19604089, 20602618].


Increased resistance of IRI is thought to be caused by increased expression of EGFR EGFR inhibitors acting on ABC transporters and UGT1A1, and modifications in the MAP kinase pathway.

In SN-38 resistant colorectal cancer lines, SN-38 up-regulates the expression of EGF and EGFR, growth factors responsible for tumor growth. EGFR inhibitors act on ABCG2 and UGT1A1. In order to promote tumor cell death, EGFR inhibitors lower the expression of these genes while simultaneously up-regulating pro-apoptotic caspase-6 and p53. Using an EGFR inhibitor in addition to SN-38 in these resistant lines may prove to defeat the resistance by increasing apoptosis in the tumor cells [Article:21997136].

In addition, SN-38 resistant cell lines display continuous activation of MAPK p38. P38 is made up of two subunits, alpha and beta. P38 alpha (MAPK14) is responsible for cell survival so inhibition of this subunit results in apoptosis (in CRC cells by SN-38, resulting in autophagy). In colorectal cancer cells with down-regulated tumor suppressor TP53, in vitro studies have proven TP53 status of tumor cells is crucial for IRI resistance. TP53 deficient CRC cell lines with up-regulated MAPK14 leads to cell growth inhibition and survival promoting autophagy, believed to be the cause of IRI resistance. Increasing rates of MAPK14 inhibits cell growth by activating TP53 dependent cell cycle arrest, as well as independently activating survival promoting autophagy. Thus, to reduce resistance, future research could be done to investigate the inhibition of MAPK14 to restore sensitivity of CRC cells to IRI. Although TP53 status is an important predictor of IRI resistance, p53 status does not seem to play a significant role [Articles:22647487, 23422270, 22665526].

Authors: Daniella Lowenberg, Caroline F. Thorn,  Michelle Whirl-Carrillo, Jackie Ramirez, Sharon Marsh, E.G. Schuetz, M.E. Dolan, F. Innocenti, Howard McLeod, Mark J. Ratain.
M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417. Full text
Therapeutic Categories:
  • Anticancer agents

Entities in the Pathway

Genes (14)

Drugs/Drug Classes (2)

Relationships in the Pathway

Arrow FromArrow ToControllersPMID
irinotecan SN-38 BCHE, CES1, CES2 10197614, 12171903
irinotecan SN-38 BCHE, CES1, CES2
SN-38 SN-38G UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9 11695848, 12893990
irinotecan irinotecan ABCB1, ABCC2 14646693, 9918583
SN-38 SN-38 ABCB1, ABCC2, ABCG2 12810652

Download data in TSV format . Other formats are available on the Downloads/LinkOuts tab.

Related Publications

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics. 2016. Hattinger Claudia M, Vella Serena, Tavanti Elisa, Fanelli Marilù, Picci Piero, Serra Massimo. PubMed